MDR reportedly causing medtech companies to leave EU market
20 Dec 2022
Reuters spoke with eight companies, including the Swedish medtech giant Getinge, who are either withdrawing from the EU market or have stopped making medical devices. The costs of complying with the MDR were simply too much.
The EU’s MDR went into effect in 2021. Medical device makers have had until 2024 to transition previously certified devices to the new standard.
Reuters reports that European doctors’ groups are already reporting medical equipment shortages. The Russia-Ukraine war has caused material shortages that have further exacerbated the problem.
EU leaders have become aware of the problems. The EU Health Commissioner Stella Kyriakides has proposed extending the transition deadline to 2027 for high-risk devices — 2028 for medium- and low-risk products. She also would like to do away with a sell-off date of May 2025 to prevent the needless disposal of devices presently on the market.
As Lisa Bartakovics of Avery Dennison Medical recently explained on our Medical Design & Outsourcing sister site, the MDR has a higher bar than the EU’s previous Medical Device Directive (MDD). Just as important, the EU isn’t allowing grandfathering into the new framework.
Said Bartakovics: “The MDR requires the legal manufacturer of a device to provide an extensive technical dossier about every product it seeks to sell in the EU. For many devices, there are heightened requirements for post-market surveillance and documentation than there were under the MDD.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.